


Volpara Scorecard

Women diagnosed during the earliest stages of breast cancer have better outcomes and survival rates.¹ Volpara® Scorecard™ software provides your breast care team with the insights they need to find cancer earlier. Easily accessed from the radiologist’s workstation, Volpara Scorecard streamlines your workflow to improve clinical decision-making and create a better patient experience.



1 shared view, many end users

① **Volpara® TruDensity™**
Automated, objective, volumetric breast density (VBD) measurements and a breast density category for an objective and consistent assessment²

② **Volpara® TruRadDose™**
Personalised radiation organ dose, consistent across manufacturers for study dose quality control

③ **Volpara® TruPressure™**
Compression pressure insights for optimal image quality and patient comfort

④ **Clear risk assessment input**
For all clinicians involved in breast care, display of average VBD%—the only validated, automated breast density measurement for the Tyrer-Cuzick 8 risk model³

Automatic density assessment + Enable risk assessment + Engage referrers = Smart screening

References

1. Clinical outcomes in very early breast cancer (≤ 1 cm): A national population based analysis. Mahvish Muzaffar, Abdul Rafeh Naqash, Nasreen A. Vohra, Darla K. Liles, and Jan H. Wong Journal of Clinical Oncology 2017 35:15_suppl, e12034-e12034.
2. Gubern-Mérida, A., Kallenberg, M., Platel, B., Mann, R.M., Marti, R. and Karssemeijer, N. (2014) Volumetric Breast Density Estimation from Full-Field Digital Mammograms: A Validation Study. PLoS ONE; 9: e85952.
3. Terry, M.B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20, 504–517 (2019).

Clinical decision support for personalized breast care

Volpara Scorecard is available to radiologists during mammography interpretation as a DICOM® Secondary Capture Image. This customisable image also includes these features:

- Volpara TruRadDose and Volpara TruPressure clinical functions, which provide quality control measures for study dose and compression pressure, respectively.
- Integration with AI software that informs the likelihood of the presence of cancerous lesions. Insights can be displayed on the Scorecard or included in DICOM Mammography CAD Structured Reports.
- Alerts that indicate when the patient meets high-risk thresholds.

Evidence for essential screening

Referring physicians and insurers require evidence of high breast density. Volpara Scorecard's objective, science-based measures help you triage women at high risk to the screening or diagnostic testing essential for better outcomes.

Effective triage for time and cost savings

Personalised screening scores help the radiologist guide a woman with high breast density to essential imaging while she's still in the facility for her annual mammogram, saving her an extra trip and the cost of scheduling an additional appointment.

Combined with Volpara® Analytics™ software, Volpara Scorecard assists in identifying patient populations with high breast density that may require additional services.

[➤ FIND OUT MORE](#)

About Volpara Scorecard

To see how Volpara Scorecard can support your breast screening program, contact your Volpara Health representative for a live demonstration, or visit our website.

About Volpara

Volpara Health is the leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara remains focused on its mission to help save families from cancer.

Why radiologists choose
Volpara's automated breast
density assessment:

4-6x

Greater risk for women with dense breasts to develop breast cancer when compared to women with fatty breasts

-30%

Sensitivity in mammographic cancer detection for women with dense breasts when compared to women with fatty breasts

89%

Average agreement with the VDG category*

96%

Average agreement with Volpara's assessment of fatty (a/b) or dense (c/d)*

*By trained, expert radiologists in clinical practice

57%

Inter-reader
agreement

77%

Intra-reader
agreement

Visual density assessment is not always consistent

Contact

info@volparahealth.com
support@volparahealth.com

AUS +61 1800 370 623
NZ +64 0800 444 148

Europe +44 203 051 1029
USA +1 800 305 3865

Connect

[f](#) @VolparaHealth

[X](#) @volpara

[in](#) Volpara Health